Profile cover photo
Profile photo
Promega Corporation
161 followers
161 followers
About
Promega Corporation's posts

Post has attachment
Don't miss Dr. Doug Wieczorek, "Strategies for Predicting Downstream NGS Success with FFPE and Circulating Cell-Free DNA Plasma Samples" at ABMF meeting Monday, March 27, 2007 10:30am. And, visit us in booth 313 to learn more about nucleic acid purification, amplification and molecular biology solutions for your laboratory. http://bit.ly/2nahWdZ
Photo

Post has attachment
Visit us at Booth 3 at the Biotherapeutics Analytical Summit to see what's new in Mass Spec. Learn about the new AccuMAP™ Low pH Protein Digestion Kits and other mass spec reagents. See our poster presentation about sample prep for biotherapeutic protein characterization. Learn more. http://bit.ly/2n0JJvX
Photo

Post has attachment
Visit us at Booth #1013 at SOT to learn about new in vitro tox assays, molecular tools and resources. We will be presenting information about a new bioluminescent Annexin V Reagent. Learn more. http://bit.ly/2mshRAA
Photo

Post has attachment
Promega Sr. Research Fellow, Dr. Said Goueli, joins a GEN expert panel to discuss the role of kinase assays in precision medicine. Read the article. http://bit.ly/2k1kOJY
Photo

Post has attachment
Read about the role of co-stimulatory and co-inhibitory cell-based assays in the development of biologics targeting immune checkpoint pathways in this GEN article. http://bit.ly/2j17LVC
Photo

Post has attachment
Promega will be presenting posters at the Frontiers in Cancer Immunotherapy Meeting at the New York Academy of Sciences February 27–28, 2017. Visit our posters on immune checkpoint and T cell activation bioassays. http://bit.ly/2ibIGpG
Photo

Post has attachment
Photo

Post has attachment
Find the smoothest ride to success with well designed PCR Assays. Join Leta Steffen, PhD for her webinar "Guidelines for Developing Robust and Reliable PCR Assays". Register today. http://bit.ly/2gZcZ60
Photo

Post has attachment
Long the "black box" of genetics, epigenetic targets are rapidly becoming the purview of drug developers. Read what Hicham Zegouti, PhD, from Promega Corporation has to say about the role of universal assays that enable HTS for small molecule drugs against epigenetic targets. http://bit.ly/2g9w7d0

Post has attachment
Misidentification and contamination of cell lines can wreck decades of research. Read what Douglas Storts, PhD, of Promega has to say in this GEN article about using STR analysis for reliable cell line authentication. http://bit.ly/2g4ahLB
Wait while more posts are being loaded